Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Betacoronavirus
/ immunology
Blood Donors
Blood Group Antigens
COVID-19
Coronavirus Infections
/ epidemiology
Female
France
/ epidemiology
Hospitalization
Humans
Incidence
Intensive Care Units
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ epidemiology
Risk
SARS-CoV-2
Sensitivity and Specificity
Seroepidemiologic Studies
Young Adult
Blood donors
Blood groups
COVID-19
SARS-CoV-2
Seroneutralisation
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
18
05
2020
revised:
03
07
2020
accepted:
08
07
2020
pubmed:
18
7
2020
medline:
8
9
2020
entrez:
18
7
2020
Statut:
ppublish
Résumé
We investigated the distribution of antibodies neutralizing SARS-CoV-2 according to age, sex or blood group in French blood donors. In 464 samples collected before the emergence of SARS-CoV-2 (2017 and 2018), our virus neutralization assay had a 100% specificity. It was used to test 998 samples collected from blood donors during the last week of March or the first week of April 2020. As expected at this stage of the outbreak, the prevalence was low (2.7%) and, importantly, criteria for blood donation imply that the vast majority of seropositives had asymptomatic or pauci-symptomatic SARS-CoV-2 infections. Seroprevalence values did not differ significantly among age groups (but were slightly higher in donors <30yo and ≥60yo), and between males and females (2.82% vs 2.69%), unlike what has been observed regarding hospitalizations admission to ICU and death rates in France. By contrast, we observed that the proportion of seropositives was significantly lower in group O donors (1.32% vs 3.86% in other donors, p = 0.014). We conclude that virus infection seems to occur with a similar incidence in men and women among French blood donors, but that blood group O persons are less at risk of being infected and not only of suffering from severe clinical presentations, as previously suggested.
Identifiants
pubmed: 32679056
pii: S0166-3542(20)30294-1
doi: 10.1016/j.antiviral.2020.104880
pmc: PMC7362788
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Blood Group Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104880Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
JAMA. 2005 Mar 23;293(12):1450-1
pubmed: 15784866
Eur J Prev Cardiol. 2020 Sep;27(13):1436-1437
pubmed: 32343152
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Virol J. 2018 Dec 27;15(1):192
pubmed: 30587193
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857